Recent News
The Two Major Mesothelioma Surgeries Have Similar Death Rates
Japanese researchers have found that the main two types of surgery for mesothelioma have similar risks of death. The surgeries either remove the diseased lung lining and one of the…
Artificial Intelligence Will Soon Help Diagnose Mesothelioma
Artificial intelligence could help treat mesothelioma in the future. Researchers in Scotland have been developing a prototype imaging system to help with diagnostics and therapeutics for the treatment of mesothelioma.…
A Combination of Tremelimumab and Durvalumab Can Extend Mesothelioma Survival
An Italian study has found that the combination of two immunotherapy drugs can create a long-term survival in mesothelioma patients. The two drugs, tremelimumab and durvalumab, were just given orphan…
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Primary Outcome Measures Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ] The primary objective is to utilize a novel prognostic algorithm to predict the outcome of MPM patients. This algorithm includes 4…
An Inhaled Vaccine Could Potentially Help Mesothelioma Patients in the Future
An inhaled vaccine could be used for mesothelioma treatment soon. Research done at MIT is showing that the inhaled vaccine can trigger an immune response for certain infections and possibly…
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma (SCITH-MESO)
Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).
A Phase III Clinical Trial is Looking at the Combination of Durvalumab and Chemotherapy to Treat Mesothelioma
A new clinical trial involving durvalumab should be closely monitored by the Food and Drug Administration. The phase III clinical trial is being performed in Baltimore, Cleveland, and Ann Arbor…
Second-Line Chemotherapy Could Help Some Peritoneal Mesothelioma Patients
Oncologists in Japan have found a way to determine which patients would best benefit from second-line chemotherapy. Second-line treatment is a second treatment that doctors perform after trying another treatment…
Second Mesothelioma Surgeries Can Help Extend Lives and Improve Quality of Life of Patients
Surgery can be hard on the body, but it can help some mesothelioma patients if done a second time. People could still have a good quality of life and even…
Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues
The purpose of the Dielectrics Properties of Thoracic Malignancies Study (DPTMS) is to provide a wealth of knowledge for investigators involved in establishing a new and effective treatment for a variety of solid tumors using tumor treatment fields. It is intended to provide biospecimen (tumor/healthy) together with demographic data (age, sex, race, occupational history, and other epidemiologic information), and clinical data (stage, treatment, survival information, and annotated CT’s). Our specific aims are to test the following hypotheses: 1) Electric properties of thoracic tumors differ from electric properties of surrounding healthy tissue 2) Different tumor types will have different electric properties 3) Electric properties of individual tumors are heterogeneous 4) Electric properties of tumors are related to the structure and composition of the underlying tissue 5) Use of standard medical imaging data (CT) will permit mapping of electric properties.
